Search clinical trials for: R-pramipexole

Total 1801 results

Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
Boehringer Ingelheim

Completed

Pivotal Study in Advanced Parkinsons Disease Patients

Parkinson Disease

Austria, Czech Republic, Hungary, India, Italy, Korea, Republic of, Philippines, Poland, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Virginia Commonwealth University
Alzheimer's Drug Discovery Foundation; University of Kansas

Completed

Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease

Alzheimer's Disease

United States
Bennett, James P., Jr., M.D., Ph.D.

Completed

R(+)PPX High Dose Treatment of ALS

Amyotrophic Lateral Sclerosis

United States
Bennett, James P., Jr., M.D., Ph.D.
University of Pittsburgh

Completed

R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Bennett, James P., Jr., M.D., Ph.D.
University of Pittsburgh; University of Nebraska

Temporarily not available

Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

Amyotrophic Lateral Sclerosis
Boehringer Ingelheim

Terminated

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

Tourette Syndrome

United States, Germany
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

Parkinson Disease

France, Germany, Netherlands
Boehringer Ingelheim

Completed

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

Healthy

China
Boehringer Ingelheim

Completed

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

Parkinson Disease
University of California, Los Angeles
University of Colorado, Denver; National Institute of Allergy and Infectious... and other collaborators

Completed

Centralized Reminder Recall - Flu RCT2

RNA Virus Infections | Respiratory Tract Infections | Influenza, Human | Orthomyxoviridae Infections | Respiratory Tract Disease | Virus Disease | Physiological Effects of Drugs | Vaccines

United States
Boehringer Ingelheim

Completed

A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.

Idiopathic Restless Legs Syndrome

Japan
Klinikum Nürnberg

Unknown

RV Septal Versus Minimized RV Pacing in Sick Sinus Syndrome (VOTE)

Sick Sinus Syndrome

Germany
First Affiliated Hospital of Zhejiang University
Hongguan biological pharmaceutical co.

Terminated

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets (PLKS-BE)

Parkinson's Disease

China
Boehringer Ingelheim

Completed

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

Parkinson Disease

China
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg

Healthy

Indonesia
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Patient Portal - Flu Reminder Recall

Respiratory Tract Infections | Influenza | Vaccines

United States
Boehringer Ingelheim

Completed

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

Restless Legs Syndrome

Japan
LifeScan

Completed

Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)

Diabetes

United States
Assistance Publique - Hôpitaux de Paris

Completed

Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban (DRIVING)

Healthy Volunteers

France
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Robotic Assisted Transanal Total Mesorectal Excision Surgery for Rectal Cancer in Low Site

Rectal Neoplasms
Sandoz

Completed

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Parkinson's Disease

Korea, Republic of
King's College Hospital NHS Trust

Unknown

Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?

Type 1 Diabetes Mellitus

United Kingdom
Northwell Health
Stanley Medical Research Institute

Completed

Cognitive Enhancement in Bipolar Disorder

Bipolar Disorder

United States
Abbott Products

Terminated

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Advanced Stage Parkinson's Disease

Germany, Italy, Portugal
Erchonia Corporation

Completed

Low Level Laser Light Therapy as an Aid to Liposuction

Pain
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Hiv

United States
Boehringer Ingelheim

Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Parkinson Disease

United States, Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Depression | Restless Legs Syndrome

Finland, France, Germany, Ireland, Italy, Korea, Republic of, Spain, Sweden, United Kingdom
Augusta University
GlaxoSmithKline

Completed

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

Restless Legs Syndrome

United States
University of Colorado, Denver
Agency for Healthcare Research and Quality (AHRQ)

Completed

Comparative Effectiveness Trial of Two Reminder/Recall Methods to Increase Immunization Rates in Young Children

Immunization Rates

United States
Boehringer Ingelheim

Completed

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

Restless Legs Syndrome

Germany, Austria, Netherlands, Norway, Sweden
Oregon Health and Science University
Boehringer Ingelheim

Completed

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease (DALI)

Parkinson's Disease

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Patient Portal Flu Vaccine Reminders_RCT 4

Respiratory Tract Infections | Influenza

United States
James A. Haley Veterans Administration Hospital

Completed

GI Surgery Pre-Operative Nutrition

Immunonutrition

United States
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus (GLIDKIR6-2)

Diabetes Mellitus

France
S.B. Konya Education and Research Hospital

Unknown

Thyroidectomy Using Ultrasonic Dissector: Is Superior Laryngeal Nerve Really Safe ?

Goiter

Turkey
ElectroCore INC

Completed

A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic Migraine

Migraine

Belgium, Denmark, Germany, Greece, Netherlands, Norway, Spain, United Kingdom
University of Pecs

Withdrawn

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor

Essential Tremor

Hungary
Boehringer Ingelheim

Completed

Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome

Restless Legs Syndrome

Austria
Teva Pharmaceuticals USA

Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Region Skane
Lund University

Completed

Pramipexole to Target "Anhedonic Depression" (PILOT-PRAXOL)

Anhedonia | Depression, Unipolar | Dysthymia | Depression, Bipolar

Sweden
Boehringer Ingelheim

Completed

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

Parkinson Disease

Austria

Search clinical trials for: R-pramipexole

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations